INTERNATIONAL STANDARD

ISO 17924

First edition 2018-10

Corrected version 2021-09

Soil quality — Assessment of human exposure from ingestion of soil and soil material — Procedure for the estimation of the human bioaccessibility/bioavailability of metals in soil

Qualité du sol — Évaluation de l'exposition humaine par ingestion de sol et de matériaux du sol — Mode opératoire pour l'estimation de la bioaccessibilité/biodisponibilité pour l'homme de métaux dans le sol

ISO 17924:2018

https://standards.iteh.ai/catalog/standards/iso/8d46caae-2ac9-402d-941a-7a434a2hf5ca/iso-17924-2018



iTeh Standards (https://standards.iteh.ai) Document Preview

ISO 17924:2018

https://standards.iteh.ai/catalog/standards/iso/8d46caae-2ac9-402d-941a-7a434a2bf5ca/iso-17924-2018



COPYRIGHT PROTECTED DOCUMENT

© ISO 2018

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office CP 401 • Ch. de Blandonnet 8 CH-1214 Vernier, Geneva Phone: +41 22 749 01 11 Email: copyright@iso.org Website: www.iso.org

Published in Switzerland

Foreword			
1	Scop	е	
2	-	native references	
3		s and definitions	
4	Bioa	ioaccessibility/Bioavailability as a concept in assessment of soils and sites with espect to human exposure	
5	Desc	ription of the mechanisms of human contaminant uptake	5
6	Desc	ription of metal binding mechanisms (speciation of metals) in soil	7
7	Use a	and interpretation of <i>in vitro</i> tests for risk assessment	8
8	8.1 8.2 8.3 8.4	ription of test method Test principle Apparatus Reagents Preparation of simulated fluids 8.4.1 General 8.4.2 Simulated saliva fluid (1 000 ml) 8.4.3 Simulated gastric fluid (1 000 ml) 8.4.4 Simulated duodenal fluid (1 000 ml) 8.4.5 Simulated bile fluid (1 000 ml) 8.4.6 pH control of mixed fluids Sample pre-treatment 8.5.1 General	9 9 10 11 11 11 13 13 14 15 15 15
ps://star	8.6	8.5.2 Preparation of test samples 8.5.3 Typical analysis protocol Sample preparation procedure The a catalog standards is 0.8d46caae-2ac9-402d-941a-7a434a2b15ca/iso-17924-2(handling, quality control and presentation of results	15 16
,	9.1 General		
	9.2	Bioaccessibility calculation	
Annex	A (in	formative) Sample preparation procedure	20
Biblio	graph	y	21

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 190, *Soil quality*, Subcommittee SC 7, *Impact assessment*.

This first edition of ISO 17924 cancels and replaces ISO/TS 17924:2007, which has been technically revised. The changes compared to the previous edition are as follows:

- 7.1 "General", 7.2 "Choosing an appropriate test", 7.3 "Description of applicable test methods" and 7.4 "Recommendations" have been deleted. 7.5 "Use and interpretation of *in vitro* tests for risk assessment" has been retained and renumbered to Clause 7:
- Clause 8 "Description of test method" has been added;
- Clause 9 (formerly Clause 8) "Data handling, quality control and presentation of results" has been completely revised;
- Annex A "Human bioaccessibility testing" has been replaced by <u>Annex A</u> "Sample preparation procedure";
- the figures have been revised;
- the complete document has been editorially revised;
- the Scope has been adapted.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

This corrected version of ISO 17924:2018 incorporates the following corrections:

— in <u>8.3.12</u>, the CAS number for magnesium chloride hexahydrate has been corrected to CAS-Nr 7786-30-3:

- in <u>8.4.1</u>, third paragraph, the sentence "The solutions are made according to detailed instructions given on the day before the extractions." has been deleted to avoid duplication of information given in the second paragraph;
- in <u>8.4.4</u>, <u>Table 9</u>, NaHCO₃, has been added with the following quantities: 5,607 g (Volume/mass made up to 500 ml), 11 214 mg/l (Final concentration);
- in <u>8.4.5</u>, <u>Table 12</u>, the mass of NaCl has been corrected to 5,230 g;
- in 8.4.5, Table 12, the mass of NaHCO₃ has been corrected to 5,796 g;
- in 8.6.17, the text "the pH should be pH = 6.3 ± 0.5 ." has been deleted, as the BARGE method does not stipulate a tolerance for the final pH.

iTeh Standards (https://standards.iteh.ai) Document Preview

ISO 17924:2018

https://standards.iteh.ai/catalog/standards/iso/8d46caae-2ac9-402d-941a-7a434a2bt5ca/iso-17924-2018

Introduction

When assessing soils contaminated with, for example, potentially harmful elements (e.g. arsenic), soil ingestion (especially by children) is often considered to be the most important exposure pathway. This assessment is often carried out on the basis of total content of the potentially harmful elements in question in the soil. However, several studies suggest that the availability of the potentially harmful elements (e.g. arsenic) in gastrointestinal tract is dependent on the form of the potentially harmful elements present and the site-specific soil chemistry. Test methods based on *in vivo* tests with, for example, juvenile swine or mini pigs are time consuming and expensive and not very compatible with the decision processes connected with the assessment and clean-up of contaminated sites. Test methods have thus been developed and validated, which involve *in vitro* laboratory tests aimed at simulating *in vivo* results. This will reduce the cost and practicalities related to the use of such testing on contaminated land.

Due to the large expenditure necessary for both private landowners and public funds set aside for the remediation of contaminated land, International Standards on the assessment of contaminated soil, especially with regard to human health, are in great demand. International Standards in this complex field will support a common scientific basis for the exchange of data, development of knowledge and sound evaluation. The aim of this document is to describe the elements of such an *in vitro* test system and give advice as to the appropriate combination and use of these elements in the specific situation. The method is based on the Bioaccessibility Research Group of Europe, Unified Bioaccessibility Method (BARGE UBM), which has been developed and agreed upon by the BARGE group.

In human health risk assessment, "bioavailability" is specifically used in reference to absorption into systemic circulation, consistent with the toxicological use of the term. This encompasses bioaccessibility, which again is a combined measure of the processes determining the interaction between the metal associated with the soil and the liquid in the human digestion system. Bioavailability furthermore includes the absorption of the contaminant through a physiological membrane and the metabolism in the liver. The bioavailable fraction is thus the fraction left after release into the human digestive liquid, transport across the intestinal epithelium and metabolism in the liver. Further description of these processes is given in Clause 4.

When considering bioavailability as the fraction of the chemical that is absorbed into systemic circulation, two operational definitions are important: absolute and relative bioavailability. Absolute bioavailability is the fraction of the applied dose that is absorbed and reaches the systemic circulation (and can never be greater than 100 percent). Relative bioavailability represents a comparison of absorption under two different sets of conditions, for example from a soil sample vs. food or another matrix used in a toxicity study, and can be greater than or less than 1. This factor can be used in exposure assessments for exposure by direct ingestion of soil, for instance if the absolute bioavailability of the metal in the specific soil is suspected to differ significantly from the absolute bioavailability implicit in the toxicity value/quality criteria used.

Soil quality — Assessment of human exposure from ingestion of soil and soil material — Procedure for the estimation of the human bioaccessibility/bioavailability of metals in soil

1 Scope

This document deals with the assessment of human exposure from ingestion of soil and soil materials. It specifies a physiologically based test procedure for the estimation of the human bioaccessibility of metals from contaminated soil in connection with the evaluation of the exposure related to human oral uptake.

The method is a sequential extraction using synthetic gastrointestinal fluids and can be used to estimate oral bioaccessibility. Soils or other geological materials, in sieved form, are extracted in an environment that simulates the basic physicochemical conditions of the human gastrointestinal tract.

This document describes a method to simulate the release of metals from soil and soil materials after passage through three compartments of the human gastrointestinal tract (mouth, stomach and small intestine). It produces extracts that are representative of the concentration of potentially harmful elements in the human gastrointestinal tract for subsequent chemical characterization.

NOTE 1 Bioaccessibility can be used to approximate oral bioavailability.

NOTE 2 The test has been validated for arsenic, cadmium and lead in an interlaboratory trial. The method has been *in vivo* validated to assess the oral bioavailability of arsenic, cadmium and lead.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 11074, Soil quality — Vocabulary

3 Terms and definitions

For the purposes of this document, the terms and definitions given in ISO 11074 and the following apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at https://www.iso.org/obp
- IEC Electropedia: available at http://www.electropedia.org/

3.1

absorption

process by which a body takes in substance and makes it a part of itself

3.2

bioaccessibility

fraction of a substance in soil or soil material that is liberated in (human) gastrointestinal juices and thus available for absorption

ISO 17924:2018(E)

3.3

bioavailability

fraction of a substance present in ingested soil that reaches the systemic circulation (blood stream)

3.4

contaminant

substance or agent present in the soil as a result of human activity

Note 1 to entry: There is no assumption in this definition that harm results from the presence of the contaminant.

3.5

dermal contact

contact with (touching) the skin

3.6

exposure

dose of a chemical that reaches the human body

3.7

exposure pathway

route a substance takes from its source to a receptor

3.8

ingestion

act of taking substances, such as soil and soil material, into the body by mouth

3.9

in vitro bioaccessibility test

bioaccessibility test carried out outside a living organism

3.10

no observed adverse effect level

NOAEL

dose at which no adverse effect on a receptor can be observed

3.11https://standards.iteh.ai/catalog/standards/iso/8d46caae-2ac9-402d-941a-7a434a2bf5ca/iso-17924-2018 pica

eating habit where usually strange and unpalatable material such as soil material and stones are consumed

Note 1 to entry: The term pica stems from the Latin name *pica pica* for the raven bird magpie which picks up randomly any kind of material for nest construction.

3.12

provisional tolerable weekly intake

PTWI

provisional weekly tolerable amount of a substance which can be taken in by a human body during a lifetime through the food chain without affecting human health

3.13

receptor

<human> potentially exposed person

3.14

relative absorption fraction

RAF

ratio between the amount of a contaminant reaching systemic circulation when ingested with, for example, soil and the same amount obtained when ingested in the toxicity experiment underlying the criteria

3.15

species

different forms of a substance always arising with each other in a reaction equilibrium

3.16

tolerable daily intake value

TDI

daily tolerable amount of a substance which can be taken in by a human body during a lifetime through the food chain without effecting human health

4 Bioaccessibility/Bioavailability as a concept in assessment of soils and sites with respect to human exposure

The characterization of bioaccessibility/bioavailability is usually performed as a part of a risk and/or exposure assessment.

Risk assessment comprises the following elements:

- hazard identification;
- dose-response assessment;
- exposure assessment;
- and based on the above: risk characterization.

An exposure assessment is the process wherein the intensity, frequency, and duration of human exposure of a contaminant are estimated, and comprises:

- source identification and characterization;
- identification of exposure routes;
- identification of relevant receptors/target groups;
- and based on this: the actual exposure assessment.

For the assessment of possible effects on human health, an analysis of the exposure routes is a prerequisite. Where receptors are not directly exposed to a contaminant, exposure assessment needs to consider the various ways by which indirect exposure might occur and the significance of them.

Human exposure from soil contamination can occur through different media.

Directly from the soil, the following exposure routes exist:

- soil ingestion, both dietary and through adherence to hands and unwashed vegetables, etc.;
- dermal contact;
- ingestion of house dust that predominantly consists of soil material.

Airborne exposure comprises the following:

- inhalation and ingestion of fugitive dust;
- inhalation of elevated outdoor-concentrations;
- inhalation of vapours that have intruded into buildings.

Exposure through food chain comprises the following:

consumption of plants including crops, wild plants and fungi;

ISO 17924:2018(E)

- consumption of animals and animal products, including wild animals;
- consumption of contaminated water.

Within this document, direct uptake of soil via ingestion and/or ingestion of fugitive dust is considered. Oral ingestion is one of the most important exposure routes for humans to soil contaminants.

Quality criteria for soil (the maximum concentration limits for soil) are usually calculated on the basis of a tolerable daily intake value (TDI) or a provisionally tolerable weekly intake (PTWI), that can be derived from the no observed adverse effect level (NOAEL) found in human data or experimental animal data. For genotoxic carcinogens for which no lower threshold for increased risk for cancer is assumed, the TDI value is set at a level that corresponds to a tolerable low (negligible) cancer risk level.

For determining the TDI, data on oral toxicity are primarily considered. These data often pertain to animal experiments where the substance is administrated to the animals mixed in the feed or in drinking water (the vehicle or transporter of the contaminant). The amount of contaminant needed to produce adverse health effects in the animal is then recorded. As an alternative, epidemiological studies relating observed human health effects to recorded exposures have been used. Most toxicological studies report the total ingested amount and seldom indicate exact values for the bioavailability of the substances administered.

When extrapolating from such experimental conditions to other conditions, e.g. to intake of contaminated soil, this approach assumes that the uptake efficiency is equal for all scenarios, i.e. that the absolute bioavailability of the contaminant is constant. The absolute oral bioavailability can be defined as the fraction of an orally ingested contaminant that reaches systemic circulation, i.e. enters the blood stream. The absolute oral bioavailability of a contaminant may range from close to 0 to almost 1 (i.e. 100 %) depending upon the physiochemical form of the contaminant. In this context, the use of the concept of absolute, oral bioavailability rests upon the assumption that adverse health effects are systemic and thus triggered by the contaminants reaching the blood stream, i.e. the internal exposure as opposed to the external exposure measured directly as intake of a contaminated medium multiplied by the concentration of the contaminant in the medium, see Figure 1.

The absolute bioavailability can be measured as the ratio between amounts in the blood of animals or man after intravenous injection (100 % bioavailability) and after oral ingestion (uptake of bioavailable fraction).




Figure 1 — Schematic presentation of oral uptake processes